SARS-CoV-2 reinfection across a spectrum of immunological states.

Justine M McKittrick, Thomas W Burke, Elizabeth Petzold, Gregory D Sempowski, Thomas N Denny, Christopher R Polage, Ephraim L Tsalik, Micah T McClain
Author Information
  1. Justine M McKittrick: Duke University School of Medicine Durham North Carolina USA.
  2. Thomas W Burke: Center for Applied Genomics and Precision Medicine Duke University Durham North Carolina USA.
  3. Elizabeth Petzold: Center for Applied Genomics and Precision Medicine Duke University Durham North Carolina USA.
  4. Gregory D Sempowski: Duke Human Vaccine Institute Durham North Carolina USA.
  5. Thomas N Denny: Duke Human Vaccine Institute Durham North Carolina USA.
  6. Christopher R Polage: Duke University School of Medicine Durham North Carolina USA.
  7. Ephraim L Tsalik: Center for Applied Genomics and Precision Medicine Duke University Durham North Carolina USA.
  8. Micah T McClain: Center for Applied Genomics and Precision Medicine Duke University Durham North Carolina USA.

Abstract

Purpose: Several cases of symptomatic reinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) after full recovery from a prior episode have been reported. As reinfection has become an increasingly common phenomenon, an improved understanding of the risk factors for reinfection and the character and duration of the serological responses to infection and vaccination is critical for managing the coronavirus disease 2019 (COVID-19) pandemic.
Methods: We described four cases of SARS-CoV-2 reinfection in individuals representing a spectrum of healthy and immunocompromised states, including (1) a healthy 41-year-old pediatrician, (2) an immunocompromised 31-year-old with granulomatosis with polyangiitis, (3) a healthy 26-year-old pregnant woman, and (4) a 50-year-old with hypertension and hyperlipidemia. We performed confirmatory quantitative reverse transcription-polymerase chain reaction and qualitative immunoglobulin M and quantitative IgG testing on all available patient samples to confirm the presence of infection and serological response to infection.
Results: Our analysis showed that patients 1 and 2, a healthy and an immunocompromised patient, both failed to mount a robust serologic response to the initial infection. In contrast, patients 3 and 4, with minimal comorbid disease, both mounted a strong serological response to their initial infection, but were still susceptible to reinfection.
Conclusion: Repeat episodes of COVID-19 are capable of occurring in patients regardless of the presence of known risk factors for infection or level of serological response to infection, although this did not trigger critical illness in any instance.

Keywords

References

  1. Front Microbiol. 2021 Jun 23;12:698169 [PMID: 34248921]
  2. Med. 2021 Jun 11;2(6):755-772.e5 [PMID: 33870241]
  3. J Infect Public Health. 2021 Jul;14(7):863-875 [PMID: 34118736]
  4. Hum Vaccin Immunother. 2020 Dec 1;16(12):3061-3073 [PMID: 33393854]
  5. Clin Infect Dis. 2021 May 18;72(10):e659-e662 [PMID: 32966566]
  6. Nature. 2021 Feb;590(7847):630-634 [PMID: 33276369]
  7. Health Sci Rep. 2022 Jul 22;5(4):e554 [PMID: 35899182]
  8. N Engl J Med. 2021 Dec 23;385(26):2487-2489 [PMID: 34818474]
  9. Rev Soc Bras Med Trop. 2020 Sep 18;53:e20200619 [PMID: 32965458]
  10. J Med Virol. 2022 Jan;94(1):44-53 [PMID: 34411311]
  11. IDCases. 2020;22:e00970 [PMID: 33029476]
  12. Chin Med J (Engl). 2020 May 5;133(9):1039-1043 [PMID: 32118639]
  13. J Reprod Immunol. 2020 Jun;139:103122 [PMID: 32244166]
  14. Int J Infect Dis. 2020 Apr;93:297-299 [PMID: 32147538]
  15. Infect Dis (Lond). 2021 May;53(5):315-324 [PMID: 33508989]
  16. Am J Emerg Med. 2021 Jan;39:256.e1-256.e3 [PMID: 32703607]
  17. Clin Infect Dis. 2021 Dec 16;73(12):2217-2225 [PMID: 33598716]
  18. J Infect. 2020 Nov;81(5):816-846 [PMID: 32619697]
  19. Am J Trop Med Hyg. 2020 Nov;103(5):1993-1996 [PMID: 32888288]
  20. IDCases. 2020;22:e00943 [PMID: 32923364]
  21. Clin Infect Dis. 2021 Nov 16;73(10):1882-1886 [PMID: 33718968]
  22. Physiol Rev. 2021 Jan 1;101(1):303-318 [PMID: 32969772]
  23. JAMA. 2020 Apr 21;323(15):1502-1503 [PMID: 32105304]

Grants

  1. 75N93019C00015/NIAID NIH HHS
  2. UC6 AI058607/NIAID NIH HHS

Word Cloud

Created with Highcharts 10.0.0reinfectioninfectionserologicalhealthyresponse2SARS-CoV-2immunocompromisedpatientscasescoronavirusriskfactorscriticaldiseaseCOVID-19spectrumstates134quantitativepatientpresenceinitialPurpose:Severalsymptomaticsevereacuterespiratorysyndromefullrecoverypriorepisodereportedbecomeincreasinglycommonphenomenonimprovedunderstandingcharacterdurationresponsesvaccinationmanaging2019pandemicMethods:describedfourindividualsrepresentingincluding41-year-oldpediatrician31-year-oldgranulomatosispolyangiitis26-year-oldpregnantwoman50-year-oldhypertensionhyperlipidemiaperformedconfirmatoryreversetranscription-polymerasechainreactionqualitativeimmunoglobulinMIgGtestingavailablesamplesconfirmResults:analysisshowedfailedmountrobustserologiccontrastminimalcomorbidmountedstrongstillsusceptibleConclusion:RepeatepisodescapableoccurringregardlessknownlevelalthoughtriggerillnessinstanceacrossimmunologicalCOVID‐19SARS‐CoV‐2antibodyimmunity

Similar Articles

Cited By